<DOC>
	<DOCNO>NCT00618345</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth cancer cell block enzymes need cell growth block blood flow cancer . PURPOSE : This phase II trial study well everolimus work treat patient relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>Everolimus Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess response rate patient relapse refractory multiple myeloma treat everolimus . Secondary - To evaluate toxicity everolimus patient multiple myeloma . - To study tumor cell blood patient enter trial laboratory correlate . OUTLINE : Patients receive oral everolimus daily day 1-28 . Treatment repeat every 4 week 12 course absence disease progression unacceptable toxicity . Patients undergo bone marrow aspirate , biopsy , blood sample collection periodically . Samples assess follow : cyclin D1 , phospho-AKT , phospho-p70 S6 kinase , phospho-S6 western blot ; checkpoint regulator PTEN , p53 , pRB , p27 immunoblotting ; p53 , Rb , p16 , PTEN , p27 , cyclin D1 DNA analysis ; caspases 3 9 immunoblotting Annexin/PI flow cytometry ; unknown molecular marker protein profile ; microvessel density . After completion study treatment , patient follow every 3-6 month 2 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma , meet 1 follow criterion : Monoclonal protein serum ≥ 1 g/dL Monoclonal light chain urine protein electrophoresis ≥ 200 mg/24 hour Measurable light chain free light chain assay ≥ 10 mg/dL Measurable plasmacytoma Must receive prior therapy relapse refractory disease PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week ANC ≥ 1,000/mm³ Platelet count ≥ 75,000/mm³ Hemoglobin ≥ 8.0 g/dL Total bilirubin ≤ 2.0 mg/dL ( total bilirubin elevate , direct bilirubin must normal ) AST ≤ 3 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN Calcium &lt; 11 mg/dL No uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior cytotoxic chemotherapy At least 2 week since prior biologic therapy radiotherapy At least 2 week since prior corticosteroid Concurrent chronic corticosteroid allow treatment disorder myeloma No concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>refractory multiple myeloma</keyword>
</DOC>